Myomo Inc.
As of Oct 22, 2026, Myomo is in Stage 2, the uptrend phase, now in week 19 (since Jun 11, 2026). It closed at $1.22, 34.4% below its 52-week high and above its 200-day average, which is rising.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care
Is MYO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MYO among Medical Devices39th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …39 | MYO | Stage 2 · wk 19 | 62 | −25.6% |
Myomo: quick answers
What stage is Myomo in?
As of Oct 22, 2026, Myomo (MYO) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 11, 2026 and is in week 19. What the four stages mean
Is Myomo in an uptrend?
Yes. Myomo is in a Stage 2 uptrend. It trades 14.0% above its 200-day average, which is rising.
How far is Myomo from its 52-week high?
Myomo closed at $1.22 on Oct 22, 2026, 34.4% below its 52-week high of $1.86. Its 52-week low is $0.64.
How has Myomo performed over the past year?
As of Oct 22, 2026, Myomo is up 8.9% over the past year and up 23.2% so far in 2026.
Which sector and industry is Myomo in?
Myomo is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.